56 citations,
August 2019 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.
5 citations,
February 2014 in “PubMed” Hair loss in Telogen effluvium is often chronic, linked to stress, and lacks a confirmed treatment, but topical corticosteroids may be used.
21 citations,
January 2016 in “Skin appendage disorders” Alfredo Rebora suggested a new, easier way to classify hair loss in Telogen Effluvium, adding a type possibly related to autoimmune diseases.
1 citations,
August 2021 in “Internal Medicine Journal” After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.
January 2018 in “Elsevier eBooks” The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.